An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung
Condition: Adenocarcinoma of Lung Interventions: Biological: JNJ-64041757; Drug: Nivolumab Sponsor: Janssen Research & Development, LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 13, 2017 Category: Research Source Type: clinical trials
